Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
May 25, 2024
Source: drugdu
116
Sucralfate is used to treat stomach ulcers,GERD, radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Strides Pharma Science (Strides) recently announced that its stepdown wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.
Sucralfate Oral Suspension, 1gm/10 mL has a market size of ~US$ 124Mn as per IQVIA (March 2024). The Sucralfate Oral Suspension, 1gm/10 mL will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.
https://www.expresspharma.in/strides-receives-usfda-approval-for-sucralfate-oral-suspension-1gm-10-ml
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Global orthopedic giant CEO may be dismissed November 15, 2024
- Johnson&Johnson Medical Technology, organizational restructuring November 15, 2024
- Uncovering the truth of AbbVie’s $8.7 billion lesson November 15, 2024
- Hospitals have a 152-day payment period, and many places have taken action to manage it November 15, 2024
- 374-year-old Chinese time-honored brand will change hands November 15, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
